- Report
- March 2023
- 75 Pages
North America
From €1337EUR$1,500USD£1,155GBP
- Report
- October 2022
- 346 Pages
Global
From €3210EUR$3,600USD£2,772GBP
- Report
- September 2022
- 292 Pages
Global
From €3210EUR$3,600USD£2,772GBP
- Report
- March 2026
- 382 Pages
China
From €4324EUR$4,850USD£3,735GBP
- Report
- March 2026
- 210 Pages
India
From €4324EUR$4,850USD£3,735GBP
- Report
- January 2026
- 150 Pages
India
From €4324EUR$4,850USD£3,735GBP
- Report
- January 2026
- 150 Pages
Japan
From €4324EUR$4,850USD£3,735GBP
- Report
- October 2025
- 150 Pages
China
From €4324EUR$4,850USD£3,735GBP
- Report
- April 2025
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- February 2025
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- November 2024
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- November 2024
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- September 2024
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- January 2024
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Report
- April 2023
- 150 Pages
Global
From €4324EUR$4,850USD£3,735GBP
- Training
- March 2025
- 2 Days
Global
From €1210EUR$1,357USD£1,045GBP
€1423EUR$1,597USD£1,229GBP
- Newsletter
- May 2026
- 4 Pages
Global
From €178EUR$200USD£154GBP
- Report
- October 2025
- 97 Pages
Saudi Arabia
From €4324EUR$4,850USD£3,735GBP
- Report
- October 2025
- 96 Pages
Saudi Arabia
From €4324EUR$4,850USD£3,735GBP
- Report
- October 2025
- 99 Pages
Qatar
From €4324EUR$4,850USD£3,735GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more